Warning letterPosted June 16, 2026
FDA warning letter to Nova Vascular LLC dba NOVARX
False & Misleading Claims/Misbranded (Telehealth)
FDA posted a warning letter to Nova Vascular LLC dba NOVARX on June 16, 2026; the letter is dated June 8, 2026. Subject: False & Misleading Claims/Misbranded (Telehealth). Issuing office: Center for Drug Evaluation and Research (CDER).
On the record
- Company
- Nova Vascular LLC dba NOVARX
- Subject
- False & Misleading Claims/Misbranded (Telehealth)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Letter dated
- 2026-06-08
- Posted by FDA
- 2026-06-16
- Source
- FDA warning letters ↗
CFR cited
The record cites 1 section of 21 CFR Part 201.
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch Nova Vascular LLC dba NOVARX
A free account shows the last 7 days of every FDA, SEC and ClinicalTrials.gov source. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with Nova Vascular LLC dba NOVARX. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.